Talecris Biotherapeutics (NASDAQ:TLCR): Q2 EPS of $0.37 in-line. Revenue of $403M (+7.2%) vs....

Talecris Biotherapeutics (NASDAQ:TLCR): Q2 EPS of $0.37 in-line. Revenue of $403M (+7.2%) vs. $399.8M. (PR)